NasdaqGM - Nasdaq Real Time Price USD

TScan Therapeutics, Inc. (TCRX)

0.1816 -0.0064 (-3.40%)

At close: November 9 at 4:00:00 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

InvestorsHub 2mo ago

TCRX
0.00%
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

GlobeNewswire 2mo ago

TCRX
0.00%
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

Zacks 2mo ago

TCRX
0.00%
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 2mo ago

TCRX
0.00%
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

GlobeNewswire 3mo ago

TCRX
0.00%
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

GlobeNewswire 4mo ago

TCRX
0.00%
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

GlobeNewswire 4mo ago

TCRX
0.00%
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Business Wire 5mo ago

TCRX
0.00%
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

Insider Monkey 5mo ago

TCRX
0.00%
AMGN
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

Zacks 6mo ago

TCRX
0.00%
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 6mo ago

TCRX
0.00%
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

GlobeNewswire 6mo ago

TCRX
0.00%

Performance Overview

Return	TCRX	S&P 500 (^GSPC)
YTD	-81.84%	+10.29%
1-Year	-83.34%	+12.20%
3-Year	-95.79%	+73.67%

U.S. markets open in 1h 35m

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting